ProfileGDS5678 / 1422862_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 65% 61% 67% 64% 64% 64% 61% 63% 67% 65% 67% 66% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9453965
GSM967853U87-EV human glioblastoma xenograft - Control 23.9172965
GSM967854U87-EV human glioblastoma xenograft - Control 33.6564961
GSM967855U87-EV human glioblastoma xenograft - Control 44.1536467
GSM967856U87-EV human glioblastoma xenograft - Control 53.8417564
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8970264
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8930964
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6446461
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7884563
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.07167
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9089565
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0577467
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0135866
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0233667